Variable | Normal CRF (n = 30) | Low CRF (n = 30) | p-value | Estimated group difference (99% CI) |
---|---|---|---|---|
Age, years, median (IQR) | 61 (55–63) | 57.5 (50–62) | 0.08b |  |
Gender, female, n (%) | 17 (57) | 17 (57) | 1.0 | na |
Education > 12 years, n (%) | 26 (87) | 20 (67) | 0.07 | na |
Diagnosis | Â | Â | Â | Â |
 Rheumatoid arthritis, n (%) | 12 (40) | 15 (50) |  |  |
 Spondyloarthritis, n (%) | 12(40) | 7 (23) |  |  |
 Psoriatic arthritis, n (%) | 6 (20) | 8 (27) | 0.38 | na |
Body fat mass, %, mean (SD)^ | 22.1 (5.2) | 31.0 (6.6) |  < 0.001a |  − 8.7 (− 12.8; − 4.5) |
VO2peak (mL/kg/min) | 34.9 (5.4) | 25.6 (4.7) |  < 0.001a | 9.4 (5.9; 12.9) |
IJD disease duration, years, median (IQR) | 16.5 (10–30) | 12.5 (7–23) | 0.23b |  |
Inflammatory markers | Â | Â | Â | Â |
 CRP, mg L−1, median (IQR) | 1 (1–2) | 2 (1–3) | 0.05b |  |
 ESR, mm h−1, median (IQR) | 9 (3–16) | 9 (5–15) | 0.74b |  |
Disease activity categorized | Â | Â | Â | Â |
 Remission, n (%) | 11 (37) | 11 (37) |  |  |
 Low, n (%) | 9 (30) | 8 (27) |  |  |
 Moderate, n (%) | 9 (30) | 5 (17) |  |  |
 High, n (%) | 1 (3) | 6 (20) | 0.20c | na |
IJD medication | Â | Â | Â | Â |
 Conventional DMARDS, n (%) | 12 (40) | 13 (43) | 0.79 | na |
 Biologics and/or JAK inhibitors, n (%) | 20 (67) | 23 (77) | 0.39 | na |
 Cortisone, n (%) | 6 (21) | 7 (23) | 0.81 | na |
 NSAIDs, n (%) | 19 (63) | 17 (57) | 0.60 | na |
Analgesics | Â | Â | Â | Â |
 Non-opioids, n (%) | 20 (67) | 22 (73) | 0.57 | na |
 Weak opioids, n (%) | 3 (10) | 4 (14) | 0.71c | na |
CVD risk factors | Â | Â | Â | Â |
 Systolic BP, mm Hg, mean (SD) | 127 (13) | 127 (13) | 0.94 |  − 0.3 (− 9.3; 8.8) |
 Diastolic BP, mm Hg, mean (SD) | 83 (10) | 84 (9) | 0.46 |  − 1.8 (− 8.4; 4.7) |
 Resting heart rate, beats/min mean (SD) | 64 (10) | 72 (12) |  < 0.01a |  − 8.0 (− 15.4; − 0.7) |
 Total cholesterol, mmol L−1, mean (SD) | 4.9 (1.3) | 4.6 (1.2) | 0.34 | 0.3 (− 0.5; 1.1) |
 HDL-c, mmol L−1, mean (SD) | 1.9 (0.4) | 1.4 (0.5) |  < 0.001a | 0.5 (0.1; 0.7) |
 LDL-c, mmol L−1, mean (SD) | 2.6 (1.2) | 2.6 (1.2) | 0.93 | 0.0 (− 0.8; 0.8) |
 Triglycerides, mmol L−1, mean (SD) | 1.1 (0.5) | 1.6 (0.8) |  < 0.01a |  − 0.5 (− 1.0; − 0.1) |
 Current use of cigarettes/snuff, n (%) | 4 (13) | 9 (30) | 0.12 | n.a |
 Presence of increased CVD risk, n (%) | 23 (77) | 26 (87) | 0.32 | na |
CVD medication | Â | Â | Â | Â |
 Statins, n (%) | 17 (57) | 17 (57) | 1.0 | na |
 Blood pressure medication, n (%) | 4 (13) | 8 (27) | 0.20 | na |
NRS 0–10, 0 = best |  |  |  |  |
 Pain, median (IQR) | 2 (1–4) | 2 (1–4) | 0.82b |  |
 Fatigue, median (IQR) | 3 (1–5) | 3.5 (1–6) | 0.52b |  |
Exercise beliefs and self-efficacy, | Â | Â | Â | Â |
(20–100, 100 = best), mean (SD)^ | 84.0 (7.3) | 77.2 (9.4) |  < 0.01a | 6.9 (1.1; 12.7) |
Physical activity index (0–45, 45 = best) |  |  |  |  |
median (IQR) | 11.3 (0–15) | 0 (0–0) | 0.02b |  |